HUTCHMED (China) Limited — FY2022 Form 20-F
Business context and reporting period. This is an annual report for the fiscal year ended December 31, 2022, not a standalone fourth-quarter filing. HUTCHMED is a commercial-stage biopharmaceutical company focused on oncology and immunology, alongside China-based pharmaceutical distribution and consumer-health ventures. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars.
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $426.4 million | $356.1 million |
| Net loss attributable to HUTCHMED | $360.8 million | $194.6 million |
| Net cash used in operating activities | $268.6 million | $204.2 million |
| Cash and cash equivalents | $313.3 million | $377.5 million |
| Short-term investments | $317.7 million | $634.2 million |
| Bank borrowings | $18.1 million | $26.9 million |
- Revenue increased 19.7%. Oncology/Immunology revenue rose 37.0% to $163.8 million; Other Ventures revenue rose 11.0% to $262.6 million.
- Elunate revenue was $69.9 million, Sulanda revenue $32.3 million, and Orpathys revenue $22.3 million. These are reported company revenues, not necessarily total product in-market sales.
- Research and development expense increased 29.4% to $386.9 million, equal to 90.7% of revenue. Total operating expenses were $834.1 million.
- Cost of revenues was $311.1 million, or 73.0% of revenue; revenue less cost of revenues was $115.3 million, a 27.0% margin, compared with 27.5% in 2021.
- Gross liquidity—cash plus short-term investments—was $631.0 million, down from $1,011.7 million. Current liabilities rose to $353.9 million from $311.7 million.
- Equity in earnings of investees was $49.8 million, down from $60.6 million, mainly reflecting the 2021 disposal of Hutchison Baiyunshan. Shanghai Hutchison Pharmaceuticals contributed $49.7 million of FY2022 equity earnings.
- No dividend has been declared or paid on HUTCHMED ordinary shares; management says it has no present plan to pay dividends.
Material changes and unusual items
- The attributable net loss widened to $360.8 million from $194.6 million. FY2021 included a $121.3 million gain on disposal of Hutchison Baiyunshan; FY2022 did not.
- Operating cash outflow increased by $64.4 million, principally because of higher operating expenses, partly offset by higher revenue and working-capital changes.
- Investing activities generated $296.6 million in cash in FY2022, largely reflecting net withdrawals from short-term investments; FY2021 investing activities used $306.3 million.
- Financing activities used $82.8 million in FY2022, versus $650.0 million generated in FY2021, when share offerings and a private placement raised substantial proceeds.
- Foreign-currency translation was an $8.5 million loss in FY2022, versus a $3.0 million gain in FY2021.
Outlook, commentary and risks
- Management said existing cash, short-term investments, expected operating cash flows, dividends from Other Ventures and available facilities were expected to fund operating expenses, debt service and capital spending for at least 12 months. This assessment depends on assumptions that may not hold.
- Management expects significant R&D spending to continue, while describing a strategic shift toward more advanced assets with nearer-term value and a focus on a path to profitability. The filing provides no specific quantitative revenue or earnings guidance.
- In January 2023, HUTCHMED agreed to license fruquintinib rights outside mainland China, Hong Kong and Macau to Takeda. The agreement is subject to customary closing conditions, including antitrust clearance. Potential consideration is up to $1.13 billion, including $400 million upfront upon closing, milestones and royalties.
- Fruquintinib’s global FRESCO-2 trial showed median overall survival of 7.4 months versus 4.8 months for placebo; the company initiated a rolling U.S. NDA submission in December 2022. The FRUTIGA gastric-cancer trial met its progression-free-survival endpoint, but overall survival was not statistically significant under the prespecified plan.
- Surufatinib received an FDA Complete Response Letter in April 2022; HUTCHMED subsequently withdrew its U.S. and European submissions. The filing says a multiregional trial would be needed to advance U.S. and European approval.
- COVID-19 restrictions disrupted research, clinical and commercial activities in 2022, particularly at Shanghai clinical sites in April and May. Restrictions in China began to ease in December 2022.
- Key risks include clinical-trial and regulatory uncertainty, commercialization and reimbursement, competition, reliance on collaborators and sole-source suppliers, manufacturing capacity, China regulatory and data-transfer rules, currency controls, and potential constraints on moving cash from China.
- The PCAOB’s December 2022 decision restored inspection access in mainland China and Hong Kong; the company did not expect to be identified under the HFCAA after this filing, but future inspection access remains a risk. Management reported effective disclosure controls and internal control over financial reporting at year-end.
- A Hong Kong arbitration award in Hutchison Sinopharm’s dispute with Luye was RMB253.2 million plus costs and interest. Luye’s appeal was pending, with a hearing set for June 2023; the company had not recognized the award as a receivable at year-end.
Important facts for investors to verify
- Whether the Takeda license closed, when the upfront payment was received, and what milestones or royalties may be achievable.
- Whether commercial growth in Elunate, Sulanda and Orpathys translates into improved margins and lower operating cash burn.
- How the reduced cash and short-term investment balance, future R&D commitments and Shanghai manufacturing-facility spending affect liquidity.
- Regulatory and clinical updates for fruquintinib, surufatinib and other priority pipeline programs, including the required multiregional trial for surufatinib in the U.S. and Europe.
- The outcome of Luye’s appeal and the timing and collectability of any award proceeds.
- Future dividends from Shanghai Hutchison Pharmaceuticals and whether China-related rules permit timely upstreaming of cash.